Management of Chronic Liver Diseases and Cirrhosis: Current Status and Future Directions

Chronic liver diseases (CLD) and cirrhosis represent a growing global health burden, affecting an estimated 1.5 billion individuals worldwide as of 2017. Over the decade spanning 2007 to 2017, age-standardized prevalence rates increased by 10.4%, driven primarily by non-alcoholic fatty liver disease (NAFLD), hepatitis B virus (HBV), hepatitis C virus (HCV), and alcohol-related liver disease (ALD). In China, NAFLD accounts for 173–310 million cases, though HBV remains the leading cause of cirrhosis despite the success of national vaccination programs. However, the age-standardized prevalence of CLD caused by HBV, HCV, and NAFLD increased by 9.0%, 10.2%, and 23.5%, respectively, during this period, underscoring the urgent need for optimized management strategies.

Etiological Landscape and Diagnostic Approaches

The etiological diversity of CLD necessitates comprehensive diagnostic evaluations to guide therapy. Screening for HBV surface antigens, HCV antibodies, metabolic panels, alcohol intake, drug exposure, and autoimmune markers (immunoglobulins, autoantibodies) is critical. Rare genetic disorders, such as Wilson disease and hemochromatosis, require specialized testing when clinical suspicion arises. Liver biopsy remains the gold standard for diagnosing fibrosis and cirrhosis but is invasive and prone to sampling variability. Non-invasive alternatives, including transient elastography (TE), aspartate transaminase-to-platelet ratio index (APRI), and Fibrosis-4 (FIB-4), are increasingly adopted to assess fibrosis severity.

Early diagnosis is paramount, as CLD often progresses silently until decompensation manifests as ascites, hepatic encephalopathy, or variceal bleeding. Advanced fibrosis, particularly in NAFLD, significantly elevates hepatocellular carcinoma (HCC) risk. Serum biomarkers (e.g., alanine transaminase, bilirubin, albumin) and imaging (ultrasound, computed tomography) complement scoring systems like Child-Turcotte-Pugh (CTP) and Model for End-Stage Liver Disease (MELD) to evaluate disease severity. For HBV-related acute-on-chronic liver failure (ACLF), the COSSH-ACLFs score predicts short-term prognosis.

Therapeutic Strategies: Current Paradigms

Management of CLD involves etiology-specific treatments, complication management, and anti-fibrotic therapies. For HBV, nucleos(t)ide analogs like tenofovir disoproxil fumarate suppress viral replication but rarely achieve functional cure (HBsAg loss). After five years of tenofovir therapy, 51% of patients exhibit fibrosis regression, highlighting the need for adjunctive therapies. In contrast, HCV is now curable with direct-acting antivirals (DAAs), achieving >95% sustained virologic response (SVR). However, drug-drug interactions (DDIs) and costs limit access.

NAFLD, particularly its inflammatory subtype non-alcoholic steatohepatitis (NASH), lacks approved pharmacotherapies. Lifestyle modifications—weight loss, dietary changes, and bariatric surgery—remain foundational, though only a minority achieve sustained weight loss. Phase 3 trials of obeticholic acid, a farnesoid X receptor agonist, demonstrated fibrosis improvement in NASH patients. Other investigational agents target metabolic pathways (peroxisome proliferator-activated receptor agonists), inflammation (C-C chemokine receptor inhibitors), and fibrogenesis.

Autoimmune and cholestatic liver diseases require distinct approaches. Autoimmune hepatitis (AIH) is managed with prednisolone and azathioprine, while mycophenolate mofetil serves as a second-line option. Primary biliary cholangitis (PBC) responds to ursodeoxycholic acid (UDCA), though refractory cases may require obeticholic acid. Drug-induced liver injury (DILI), increasingly linked to antibiotics, mandates prompt drug cessation and occasionally immunosuppression.

Complications and Portal Hypertension Management

Portal hypertension (PHT), a major consequence of cirrhosis, drives morbidity through variceal bleeding, ascites, and hepatorenal syndrome. Acute variceal bleeding is managed with vasoactive agents (terlipressin, octreotide) and endoscopic interventions. Non-selective beta-blockers (carvedilol, propranolol) prevent rebleeding, while transvenous obliteration and esophageal stents offer rescue therapies. Statins, once contraindicated, now show promise in reducing PHT progression by modulating sinusoidal resistance and improving endothelial function.

Ascites management prioritizes diuretics and albumin infusion, with transjugular intrahepatic portosystemic shunts (TIPS) reserved for refractory cases. Hepatic encephalopathy (HE) requires lactulose and rifaximin to reduce ammonia levels. Hepatorenal syndrome (HRS) demands vasoconstrictors (terlipressin) with albumin, though liver transplantation remains definitive therapy.

Emerging Therapies and Future Directions

The pursuit of HBV cure focuses on eliminating covalently closed circular DNA (cccDNA) and restoring immune control. Nucleic acid polymers like REP 2139/2165 disrupt subviral particle assembly, achieving HBsAg loss in phase 2 trials. Immunotherapies targeting innate (Toll-like receptors, natural killer cells) and adaptive (HBV-specific T and B cells) immunity are under investigation.

For NASH, combination therapies addressing metabolic dysregulation, inflammation, and fibrosis are anticipated. Vitamin E, glucagon-like peptide-1 agonists, and thyroid hormone receptor beta agonists show potential in early trials. Similarly, chronic DILI management may benefit from biomarkers predicting idiosyncratic reactions and personalized drug safety profiles.

Global Challenges and Opportunities

Despite progress, disparities in access to DAAs and HBV therapies persist, particularly in low-resource settings. NAFLD’s rise parallels global obesity trends, necessitating public health interventions. In China, HBV vaccination has reduced transmission, yet existing infections require long-term antiviral therapy. HCC surveillance, utilizing alpha-fetoprotein (AFP) and protein induced by vitamin K absence-II (PIVKA-II), remains vital for early detection.

In conclusion, CLD and cirrhosis management hinges on early diagnosis, etiology-specific treatment, and complication prevention. While DAAs revolutionized HCV care, HBV cure and NASH therapies represent unmet needs. Emerging agents targeting viral persistence, metabolic pathways, and immune regulation, coupled with non-invasive diagnostics, promise to transform outcomes. Multidisciplinary approaches integrating hepatology, immunology, and public health will be essential to curb the growing burden of liver disease globally.

doi.org/10.1097/CM9.0000000000001084

Was this helpful?

YesNo

0 / 0